Table 5 Reviewing the studies on post-vaccination headache

Serwaa, Ghana [13]

Cross-sectional

654

Personnel

AstraZeneca

27.3% 178

García-Azorín, Norway [14]

Cross-sectional

77

General

Non-replicant adenovirus vector-based vaccines

49.4% 38

Ekizoglu, Turkey [15]

Cross-sectional

1819

Personnel

CoronaVac (Pfizer)

30.6% 556

Göbel, Germany [16]

Cohort

12,000

General

ChAdOx1 nCoV-19

19.5% 2340

Sekiguchi, Japan [17]

Cross-sectional

171

Personnel

Pfizer

39.7% 68

Hatmal, Jordan [18]

Cross-sectional

2213

General

Sinopharm, AstraZeneca, Pfizer-BioNTech

46.9% 1038

Solomon, Ethiopia [18]

Cross-sectional

672

Personnel

AstraZeneca

50.2% 337

Adam, Saudi Arabia [19]

Cross-sectional

330

General

Pfizer, AstraZeneca

24.2% 86

Pokharel, Nepal, [20]

Cross-sectional

220

Personnel

Covishield

19.5% 43

Klugar, Czech Republic

[21]

Cross-sectional

599

Personnel

Pfizer, AstraZeneca

53.6% 321

Saeed, UAE [22]

Cross-sectional

1102

General

Sinopharm

10.0% 110

Almufty, Iraq [23]

Cross-sectional

1012

General

Pfizer, AstraZeneca, Sinopharm

34.0% 344

Quiroga, Spain [24]

Cross-sectional

708

General

Pfizer

34.0% 240

Cuschieri, Malta [25]

Cross-sectional

1480

Personnel

Pfizer

44.2% 655

Kaya, Turkey [26]

Cohort

329

Personnel

Pfizer

16.8%, 56

Raid, Czech Republic [27]

Cross-sectional

92

Personnel

AstraZeneca

29.3%, 27

Abu-Hammad, Jordan

[28]

Cross-sectional

409

Personnel

Pfizer, AstraZeneca, Sinopharm

42.0% 172

Lee, Seoul Korea [29]

Cross-sectional

265

Personnel

Pfizer

48.7% 129

Zhang, China [30]

Cross-sectional

1526

Personnel

Pfizer

6.0% 92

El-Shitany, Saudi Arabia

[31]

Cross-sectional

124

General

Pfizer

22.5% 28

Kadali, USA [32]

Cross-sectional

1245

Personnel

Pfizer

45.4% 565

Kim, Seoul Korea [33]

Cross-sectional

1403

Personnel

Pfizer, AstraZeneca

47.4% 665

Our study, Iran

Cross-sectional

334

Personnel

AstraZeneca, Sinopharm Sputnik v Bharat, Co Iran barekat

39.2% 131